|
|
|
ONLINE FEATURES
Book Reviews
BW Video
Columnists
Interactive Gallery
Newsletters
Past Covers
Philanthropy
Podcasts
Special Reports
BLOGS
The Auto Beat
Byte of the Apple
Europe Insight
Eye on Asia
Getting In
Investing Insights
The New Entrepreneur
NEXT: Innovation Tools & Trends
On Media
Technology at Work
The Tech Beat
Traveler's Check
TECHNOLOGY
Product Reviews
Tech Stats
Hands On
AUTOS
Home Page
Auto Reviews
Car Care & Safety
INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip FINANCE Investing: Europe Annual Reports Bloomberg BW50 SCOREBOARDS Hot Growth Companies: 2008 Mutual Funds Info Tech 100 B-SCHOOLS Undergrad Programs Rankings & Profiles |  |
JANUARY 19, 2004
By Gene G. Marcial Sniffing For Anthrax  Little-known Cepheid (CPHD
) has caught the eye not only of traders but also of long-term big investors. Its shares rocketed from 4 in August to 10.50 on Jan. 5. (The stock was featured in this column on Sept. 23, 2002, at 3.74.) "Despite the runup, the stock is way undervalued," says Elemer Piros of Rodman & Renshaw, who sees it at 17 in a year.
The U.S. Postal Service has signed up Cepheid to install 1,784 systems to detect anthrax at 284 mail-sorting facilities. The Postal Service will spend $75 million to $100 million annually for Cepheid's devices, which it developed with Northrop Grumman (NOC ). They test the air every hour for harmful particles, notes Piros. Installation will be finished by 2006, when Piros expects Cepheid to turn profitable. Its bio-defense business alone is worth at least 10 a share, he figures. Other Cepheid products, including clinical diagnostics for Group B Streptococcus and an antibiotic-resistance test, are worth about 7, he adds. Piros says Cepheid may also be working on a test for animal feed to halt the spread of mad cow disease, using the same technology the Postal Service approved for bio hazards. Cepheid didn't return calls. Al Kildani of C.E. Unterberg, Towbin, says $50 million to $75 million of the Postal Service's funding for bio-threat devices will go to Cepheid itself -- up from his previous estimate of $32 million to $35 million. The rest goes to Northrop. He rates Cepheid a buy for the short and long term. Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.  See Gene Marcial on Fridays at 1:20 p.m. EST on CNNfn's The Money Gang. Get BusinessWeek directly on your desktop with our RSS feeds.  Add BusinessWeek news to your Web site with our headline feed. Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video. To subscribe online to BusinessWeek magazine, please click here. Learn more, go to the BusinessWeekOnline home page  | | |
 Copyright 2004, Bloomberg L.P.Terms of Use | Privacy Notice |
Printer-Friendly Version
